Clarus Therapeutics Holdings Inc. (CRXT): Don’t disregard this ominous signal – Invest Chronicle

Clarus Therapeutics Holdings Inc. (CRXT): Don’t disregard this ominous signal

Let’s start up with the current stock price of Clarus Therapeutics Holdings Inc. (CRXT), which is $0.42 to be very precise. The Stock rose vividly during the last session to $0.437 after opening rate of $0.3509 while the lowest price it went was recorded $0.3509 before closing at $0.36.Recently in News on June 9, 2022, Clarus Therapeutics to Present New Data for JATENZO® (testosterone undecanoate) at ENDO 2022, the Endocrine Society’s Annual Meeting. JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions. You can read further details here

Clarus Therapeutics Holdings Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.9400 on 04/20/22, with the lowest value was $0.3302 for the same time period, recorded on 05/26/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Clarus Therapeutics Holdings Inc. (CRXT) full year performance was -95.81%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Clarus Therapeutics Holdings Inc. shares are logging -98.65% during the 52-week period from high price, and 27.92% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.33 and $31.24.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 5087109 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the Clarus Therapeutics Holdings Inc. (CRXT) recorded performance in the market was -82.62%, having the revenues showcasing -64.20% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 23.00M, as it employees total of 16 workers.

Market experts do have their say about Clarus Therapeutics Holdings Inc. (CRXT)

During the last month, 3 analysts gave the Clarus Therapeutics Holdings Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 0.9045, with a change in the price was noted -0.85. In a similar fashion, Clarus Therapeutics Holdings Inc. posted a movement of -66.74% for the period of last 100 days, recording 9,235,600 in trading volumes.

Technical breakdown of Clarus Therapeutics Holdings Inc. (CRXT)

Raw Stochastic average of Clarus Therapeutics Holdings Inc. in the period of last 50 days is set at 2.55%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 41.95%. In the last 20 days, the company’s Stochastic %K was 22.32% and its Stochastic %D was recorded 17.17%.

Bearing in mind the latest performance of Clarus Therapeutics Holdings Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -82.62%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -86.55%, alongside a downfall of -95.81% for the period of the last 12 months. The shares 14.91% in the 7-day charts and went up by 7.76% in the period of the last 30 days. Common stock shares were lifted by -64.20% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts